The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
----------
Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Hires Jeyan Heper as chief operating officer, starting from February 1. Says that he held senior executive roles in brand management at Procter & Gamble Co and marketing at Danone SA. Says that Chief Executive Peter Butterfield will return to the business in the first quarter of 2023 on a phased basis. Decides to appoint an interim CEO who is expected to join the board and focus on strategic delivery and external stakeholder engagement.
----------
Empire Metals Ltd - London-based minerals explorer and developer - Says that the exploration field work at its at Pitfield copper project in Western Australia is progressing well. Says that the project has the potential to contain multiple sediment-hosted stratabound copper deposits. Says the field work has been focused on under-explored areas of the project to generate new exploration data. ‘Great progress has been made on our two main exploration camps at Pitfield and Eclipse-Gindalbie over recent weeks as we set ourselves up for a major exploration push during H1 2023. What is particularly exciting is that we have found a way to speed up our field activities at Pitfield, having been able to contract an IP surveying team that could mobilise to site in mid-December, well ahead of our previously announced exploration schedule,’ Executive Director Shaun Bunn says.
----------
Real Estate Credit Investments Ltd - specialist investor in European real estate credit markets - Net asset value per share as at December 31 stands at £1.482 per share, representing a decrease of 2.0p per share from £1.502 per share as at November 30. Attributes this to the payment of the second interim dividend of 3.0p and 1.0p of interest income. Continues to see a growing pipeline of senior loans at attractive floating rates. Expects to re-invest their repayments into high-returning deals in 2023.
----------
Midatech Pharma PLC - Cardiff-based R&D biotechnology company focused on improving the bio-delivery and bio-distribution of medicines - Plans to begin the dose escalation in its MTX-110 trial after the first month of treatment and a positive recommendation from the study’s data safety monitoring board. The phase I study is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX-110, it adds.
----------
Copyright 2023 Alliance News Ltd. All Rights Reserved.
